Arthritis & Rheumatism, Volume 63,
November 2011 Abstract Supplement
Abstracts of the American College of
Rheumatology/Association of Rheumatology Health Professionals
Annual Scientific Meeting
Chicago, Illinois November 4-9, 2011.
Spanish LupusPRO: Cross Cultural Validation Study for Lupus.
Jolly1, Meenakshi, Block1, Joel A., Mikolaitis1, Rachel A., Wallace2, Daniel, Duran-Barragan3, Sergio, Bertoli4, Ana M., Toloza5, Sergio
Rush University Medical Center, Chicago, IL
USC Keck Schl of Medicine, Los Angeles, CA
Cedars Sinai Med Ctr, Los Angeles, CA
University of Alabama at Birmingham, Birmingham, AL
Cedars-Sinai/UCLA, Los Angeles, CA
UIECD, Guadalajara, Mexico, Guadalajara, Mexico
Instituto Reumatológico Strusberg, Cordoba, Cordoba, Argentina
Hospital San Juan Bautista, Catamarca, Argentina
University of Buenos Aires, Buenos Aries, Argentina
University of PuertoRico Medical Sciences Campus, San Juan, PR
Harbor UCLA Medical Center, Torrance, CA
Loma Linda Univ, Loma Linda, CA
LupusPRO is a disease targeted Patient Reported Outcome measure that was developed and validated from and among US patients with Systemic Lupus Erythematosus (SLE). We herein report the results of the cross-cultural validation study of the Spanish translated version of the LupusPRO.
Forward and back translations of the 43 item English LupusPRO were undertaken and pretested in five individuals. The finalized Spanish version was applied to the SLE patients meeting ACR classification criteria of Hispanic ancestry from the US and Latin America. Demographic, clinical and serological characteristics were obtained and the SF-36 (Spanish) and Spanish LupusPRO (T1) administered. Disease activity was ascertained using the physician Global Assessment (PGA), SELENA-SLEDAI and LFA defined Flare (Yes/No). Disease damage was assessed using the SLICC-ACR SDI. A mail back Spanish LupusPRO to be completed within 23 days (T2) was also given. Internal consistency reliability (ICR), test-retest reliability (TRT), criterion validity (against measures of disease activity or health status) and convergent validity (corresponding domains of the SF36) were all tested. All reported p values are two tailed.
211 SLE subjects (90% women) were enrolled. Sixty-four percent had upto High School education, and 46% were currently married. The mean ± SD age (yrs) and disease duration were 38 ± 12 and 8.8 ±7.6. The mean ± SD PGA and SLEDAI were 0.78 ±0.76 and 3.9 ±4.4. The mean ± SD SDI were 0.61 ± 1.1. Psychometric properties are shown in the table.
Table Psychometric Properties of Spanish LupusPRO
|Domain||ICR T1||ICR T2||TRT||Conv. Validity (corr r, p)||Criterion Validity (p value)|
|Lupus Symptoms||0.67||0.73||0.94||LFA Flare (p 0.001), Flare severity (0.007), Patient-Change in Health (0.01), SF36-Overall Health (0.0001), PGA (0.0001), SLEDAI (0.01)|
|Cognition||0.91||0.93||0.9||LFA Flare (0.01), Flare severity (0.06), Patient-Change in Health (0.03), SF36-Overall Health (0.0001), PGA (0.0001),SLEDAI (0.04)|
|Lupus Medications||0.74||0.74||0.89||LFA Flare (0.04), SF36-Overall Health (0.001),PGA (0.002), SLEDAI (0.03)|
|Physical Health||0.87||0.93||0.95||SDI (-0.15, 0.04), PF (0.64, 0.001), RP(0.61, 0.001)||LFA Flare (0.001), Flare severity (0.01), Patient-Change in Health (0.0001), SF36-Overall Health (0.0001),PGA (0.0001), SLEDAI (0.0001)|
|Pain-Vitality||0.94||0.95||0.96||BP (0.78, 0.001), VT (0.73, 0.001)||LFA Flare (0.002), Flare severity (0.003), Patient-Change in Health (0.0001),SF36-Overall Health (0.0001), PGA (0.0001), SLEDAI (0.003)|
|Body Image||0.95||0.96||0.96||LFA Flare (0.001), Flare severity (0.002), Patient-Change in Health (0.06), SF36-Overall Health (0.0001), PGA (0.0001), SLEDAI (0.008)|
|Emotional Health||0.93||0.95||0.97||EH (0.67, 0.001), RE (0.64, 0.001)||LFA Flare (0.002), Flare severity (0.006), SF36-Overall Health (0.0001),PGA (0.001), SLEDAI (0.03)|
|Desires-Goals||0.88||0.93||0.93||LFA Flare (0.01), Flare severity (0.07), Patient-Change in Health (0.01), SF36-Overall Health (0.0001), PGA (0.001), SLEDAI (0.001)|
|Satisfaction Med Care||0.86||0.5||0.8|
The Spanish LupusPRO has fair psychometric properties and is now available to be included in Latino-American clinical trials and in longitudinal studies for testing of responsiveness to change.
To cite this abstract, please use the following information:
Jolly, Meenakshi, Block, Joel A., Mikolaitis, Rachel A., Wallace, Daniel, Duran-Barragan, Sergio, Bertoli, Ana M., et al; Spanish LupusPRO: Cross Cultural Validation Study for Lupus. [abstract]. Arthritis Rheum 2011;63 Suppl 10 :1860